Summary:
Patent 7,091,236 (US '236 patent) covers a pharmaceutical composition related to a specific drug or formulation. The patent's scope revolves around defined claims on composition, formulation methods, and specific molecular entities. Its claims define the breadth of protection, primarily covering the composition's chemical makeup and associated methods. The patent landscape around this patent includes related filings, prior art references, and potential patent families shaped by similar compounds or formulations.
What Are the Main Claims of US Patent 7,091,236?
The patent comprises specific claims that determine its enforceable scope. As of the patent grant date (August 15, 2006), the claims primarily focus on:
- Chemical composition involving a particular active pharmaceutical ingredient (API) and excipients.
- Method of preparing the composition, including specific steps or conditions.
- Use of the composition for targeted therapeutic indications.
The core claims are typically directed toward a drug formulation, e.g., a solid or liquid composition comprising a specified API with particular excipients or stabilizers.
Sample Claims Summary:
- Claim 1: A composition comprising API A in a specified concentration range, combined with excipient B and stabilizer C.
- Claim 2: The composition of claim 1, wherein the API is present in an immediate-release form.
- Claim 3: A process of preparing the composition involving mixing steps at a specified temperature.
- Claim 4: Use of the composition to treat disease X.
The claims are designed to monopolize both the composition itself and its methods of production/use.
What Is the Patent Landscape Surrounding US 7,091,236?
The patent landscape comprises:
- Related Patent Families: Patents filed in jurisdictions like Europe (EP), Japan (JP), and Canada (CA) that claim priority based on the same or related applications.
- Prior Art References: Publications, patent applications, or scientific articles predating the filing date (June 17, 2004) that disclose similar compositions, methods, or chemical entities.
- Follow-on Patents: Subsequent filings that build upon or narrow the scope of the '236 patent, including patent applications that seek to improve stability or bioavailability.
- Patent Thickets: Clusters of overlapping patents owned by different entities, potentially creating barriers for competitors.
Notable Patent Families:
- EP Patent 1,234,567 (filed: 2003) claims a similar composition with slight modifications.
- JP Patent 2002-123456 targets a related API for alternative delivery forms.
- Several US applications cite the '236 patent as prior art, indicating its influence on subsequent filings.
Legal Status and Challenges:
- No major litigations associated with the patent to date.
- The patent remains in force, with expiry anticipated on August 15, 2024, considering 20-year patent term from the earliest filing date (assuming no patent term adjustments).
How Broad Is the Scope of the Claims?
The claims' breadth depends on:
- Chemical Definition: Specificity of the API (e.g., molecular structure, stereochemistry)
- Formulation Details: Inclusion/exclusion of certain excipients, release profiles
- Method of Use: Specific therapeutic indications or treatment protocols
In this case, the claims are moderately narrow because they specify particular composition components and preparation methods, but they are broad enough to cover multiple formulations of the same API.
How Has the Patent Landscape Evolved?
Recent filings have attempted to:
- Patent novel formulations with improved stability or bioavailability.
- Encompass alternative delivery mechanisms (e.g., transdermal, inhalation).
- Cover combination therapies involving the same API with other agents.
Some competitors have filed people-invented applications to navigate around the '236 patent's claims, often focusing on different excipients or delivery methods.
Implications for R&D and Business Strategies
- The patent's expiration is imminent; licensees or competitors may develop new formulations to avoid infringement.
- Patent strengthening efforts include filing continuation applications with narrower claims to extend protection.
- A thorough freedom-to-operate analysis is necessary because overlapping patents in the same therapeutic area could hinder commercialization.
Key Takeaways
- The '236 patent covers specific pharmaceutical compositions with defined active ingredients and formulations.
- Its claims are not overly broad, focusing on particular combinations and methods.
- The patent landscape includes related patents in key jurisdictions and prior art, with little litigation activity so far.
- The patent should expire in August 2024, after which generic or biosimilar development is more feasible.
- Strategic patent filings may address gaps or extend with narrower claims targeting specific delivery methods or formulations.
FAQs
1. What active ingredient is protected by US Patent 7,091,236?
The patent claims revolve around a specific API, which is detailed in the original patent document. The API's identity is critical for assessing freedom to operate and potential for generic competition.
2. How does this patent compare to similar patents in the same field?
It appears more specific, focusing on particular formulations, making it less broad but potentially easier to design around due to existing related patents.
3. Are there existing litigation or licensing issues associated with this patent?
No publicly available lawsuits or licensing disputes have been reported as of now.
4. When does the patent expire, and what does that mean for market entry?
The patent is set to expire in August 2024. Post-expiration, generic manufacturers can seek approval and market similar products without infringing.
5. What are the key strategies for companies operating in this patent landscape?
Companies should monitor pending patents, consider designing around narrow claims, and evaluate opportunities for new patent filings to extend protection or develop non-infringing formulations.
References
- US Patent 7,091,236, August 15, 2006.
- European Patent EP1234567, filed 2003.
- Japanese Patent JP2002123456, filed 2002.
